Xcovery Announces Presentation Of Clinical Data At Upcoming ASCO Annual Meeting
Phase I Study Is First-in-Human Trial of an Oral VEGFR Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Solid Tumors
West Palm Beach, FL (Marketwire) - Xcovery, a developer of next-generation targeted therapeutics for cancer, today announced that investigators will present data from its Phase 1 clinical study which evaluated X-82, an oral VEGFR tyrosine kinase inhibitor (TKI), in patients with advanced solid tumors.
The data will be presented in a poster presentation at the American Society of Clinical Oncology's (ASCO) Annual Meeting taking place on Friday, June 1 through Tuesday, June 5, 2012 in Chicago.
Poster PresentationTitle: A Phase I First-in-Human Trial of an Oral VEGFR Tyrosine Kinase Inhibitor (TKI), X-82, in Patients with Advanced Solid Tumors
Date & Time: Monday, June 4, 2012: 8:00 AM - 12:00 PM, CT
Location: S Hall, A2
The poster will be made available for viewing on the company's website, www.xcovery.com, following the public presentation.
VEGFR tyrosine kinase inhibitors have demonstrated benefit in a variety of cancers. However, it has been well documented that the dosage and use of this class in combination with other therapies has been limited by side effects.
Xcovery's lead clinical candidate, X-82, is a novel, potent, oral dual VEGFR/PDGFR inhibitor, designed to minimize side effects. The preliminary Phase 1 data described in this poster presentation suggests that X-82 has unique pharmacokinetic and pharmacodynamic properties which differentiate it from competitive products in development and on the market.
Xcovery is a clinical-stage company focused on the development of next-generation targeted therapeutics for cancer. Founded by Sheridan G. Snyder and Chris Liang, PhD, Xcovery's vision is to successfully develop innovative oncology therapies to optimize patient outcomes. Through innovative drug design, Xcovery has developed a comprehensive pipeline of oncology therapies that target a wide range of advanced tumors. X-82 was developed by Tyrogenex, an Xcovery company, funded by Biocatalyst International.